<DOC>
	<DOCNO>NCT00203372</DOCNO>
	<brief_summary>The purpose study evaluate safety TAC-bevacizumab combination investigate whether change gene expression , expression specific biomarkers , either predictive response bevacizumab indicative response .</brief_summary>
	<brief_title>Neoadjuvant TAC Plus Minus Bevacizumab ( AVF3299 )</brief_title>
	<detailed_description>The study combine bevacizumab efficacious combination chemotherapy regimen treatment stage II stage III primary breast cancer . Safety TAC-bevacizumab combination evaluate . In addition , study design incorporate initial cycle bevacizumab placebo alone . Assessing isolated effect bevacizumab set pre- post-treatment tissue specimen obtain provide essential information mechanism VEGF inhibition affect tumor growth , represent ideal opportunity evaluate molecular effect bevacizumab breast tumor tissue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically cytologically proven adenocarcinoma breast Stage II ( T &gt; 3 cm ) Stage III disease ( except inflammatory breast cancer ) , accord AJCC Staging Manual , 6th Edition , 2002 HER2negative disease ( define fluorescence situ hybridization [ FISH ] ) ECOG performance status 01 No prior chemotherapy , radiotherapy , endocrine therapy invasive noninvasive breast cancer Normal cardiac function ( ejection fraction &gt; low limit normal ) determine MUGA echocardiogram Adequate organ function Prior chemotherapy radiotherapy Stage II Stage III breast cancer Inflammatory Breast Cancer , clinically define presence erythema induration involve onethird breast Prior treatment antiangiogenic agent Prior ipsilateral radiation therapy invasive noninvasive breast cancer Bilateral invasive breast cancer Concurrent therapy nonprotocol anticancer therapy Current therapy hormone replacement therapy , hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators ( agent must stop prior randomization ) Presence neuropathy &gt; grade 2 ( NCICTC version 3.0 ) baseline Presence nonhealing wound , bone fracture , ulcer , presence clinically significant ( &gt; grade 2 ) peripheral vascular disease History malignancy within past 5 year , exception nonmelanoma skin cancer carcinomainsitu cervix Clinically significant cardiovascular disease ( e.g. , hypertension [ BP &gt; 150/100 ] , myocardial infarction stroke within 6 month , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication Active peptic ulcer disease , inflammatory bowel disease , gastrointestinal condition increase risk perforation ; history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior begin therapy Active , uncontrolled infection require parenteral antimicrobial The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place subject undue risk treatment complication Pregnancy lactation A history severe hypersensitivity reaction bevacizumab , docetaxel drug formulate polysorbate 80 Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior begin therapy , anticipation need major surgical procedure course study ; minor surgical procedure , fine needle aspiration , core biopsy within 7 day prior begin therapy Urine protein : creatinine ratio &gt; 1.0 screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>